Sign Out
Pregnancy: As precautionary measure, irbesartan should preferably not be used during first trimester of pregnancy. A switch to a suitable alternative treatment should be carried out in advance of a planned pregnancy. In the second and third trimesters, substances that act directly on the renin-angiotensin system can cause foetal or neonatal renal failure, foetal skull hypoplasia and even foetal death, therefore, irbesartan is contraindicated in the second and third trimester of pregnancy. If pregnancy is diagnosed, irbesartan should be discontinued as soon as possible, skull and renal function should be checked with echography if, inadvertently, the treatment was taken for a long period.
Lactation: Irbesartan is contraindicated during lactation. It is not known whether irbesartan is excreted in human milk. Irbesartan is excreted in the milk of lactating rats.
